ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 941,64
0,88%
Dow Jones
44 968,45
0,57%
DAX
21 727,20
0,48%
Brent Oil
75,855
-0,09%
Bitcoin
105 609,58
1,80%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Lipella Pharmaceuticals Inc (LIPO) Cours

Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc (LIPO)

NASDAQ
2,69
-0,02
( -0,74% )
Mis à jour : 19:30:04
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
2,69
Prix Achat
2,70
Prix Vente
2,76
Volume échangé
13 447
2,60 Fourchette du Jour 2,79
2,21 Plage de 52 semaines 12,00
Cap du marché
3,252M
Clôture Veille
2,71
Ouverture
2,66
Dernière Transaction
10
@
2.76
Dernière heure de transaction
19:46:23
Volume financier
US$ 36 208
VWAP
2,6926
Volume moyen (3 m)
152 305
Actions en circulation
1 208 919
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,70
Bénéfice par action (BPA)
-3,82
Chiffre d'affairess
450k
Bénéfice net
-4,62M

À propos de Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.lipella.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Lipella Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker LIPO. Le dernier cours de clôture d'Lipella Pharmaceuticals était de US$2,71. Au cours de la dernière année, les actions de Lipella Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 2,21 à US$ 12,00.

Lipella Pharmaceuticals compte actuellement 1 208 919 actions en circulation. La capitalisation boursière d'Lipella Pharmaceuticals est de US$3,28 million. Lipella Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -0.70.

LIPO Dernières nouvelles

Plus de nouvelles

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

24 Janvier 2025
Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

24 Janvier 2025
Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

18 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

18 Janvier 2025
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

16 Janvier 2025
Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness

16 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

13 Janvier 2025
Edgar (US Regulatory)

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) --  Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements...

10 Janvier 2025
GlobeNewswire Inc.

Form D - Notice of Exempt Offering of Securities

07 Janvier 2025
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

07 Janvier 2025
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.23-7.876712328772.922.952.6295662.76802591CS
4-0.43-13.78205128213.123.72.6557393.10730404CS
120.0180.6736526946112.6723.72.211523052.95766688CS
26-3.5284-56.74128393166.21847.74962.217120033.83249575CS
52-5.4804-67.07627533548.1704122.2111593446.12808902CS
156-53.47-95.210113960156.1661.762.2176369310.16281959CS
260-53.47-95.210113960156.1661.762.2176369310.16281959CS

LIPO - Frequently Asked Questions (FAQ)

What is the current Lipella Pharmaceuticals share price?
The current share price of Lipella Pharmaceuticals is US$ 2,69
How many Lipella Pharmaceuticals shares are in issue?
Lipella Pharmaceuticals has 1 208 919 shares in issue
What is the market cap of Lipella Pharmaceuticals?
The market capitalisation of Lipella Pharmaceuticals is USD 3,28M
What is the 1 year trading range for Lipella Pharmaceuticals share price?
Lipella Pharmaceuticals has traded in the range of US$ 2,21 to US$ 12,00 during the past year
What is the PE ratio of Lipella Pharmaceuticals?
The price to earnings ratio of Lipella Pharmaceuticals is -0,7
What is the cash to sales ratio of Lipella Pharmaceuticals?
The cash to sales ratio of Lipella Pharmaceuticals is 7,23
What is the reporting currency for Lipella Pharmaceuticals?
Lipella Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Lipella Pharmaceuticals?
The latest annual turnover of Lipella Pharmaceuticals is USD 450k
What is the latest annual profit for Lipella Pharmaceuticals?
The latest annual profit of Lipella Pharmaceuticals is USD -4,62M
What is the registered address of Lipella Pharmaceuticals?
The registered address for Lipella Pharmaceuticals is 108 WEST 13TH STREET, WILMINGTON, DELAWARE, 19801
What is the Lipella Pharmaceuticals website address?
The website address for Lipella Pharmaceuticals is www.lipella.com
Which industry sector does Lipella Pharmaceuticals operate in?
Lipella Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
FOXXFoxx Development Holdings Inc
US$ 10,27
(255,36%)
26,01M
AMODAlpha Modus Holdings Inc
US$ 3,661
(137,73%)
115,23M
TECXTectonic Therapeutic Inc
US$ 50,45
(96,15%)
4,4M
ACONAclarion Inc
US$ 16,15
(75,31%)
2,54M
ATHEAlterity Therapeutics Limited
US$ 4,51
(54,98%)
20,41M
CLEUChina Liberal Education Holdings Ltd
US$ 0,2087
(-97,31%)
192,79M
CRGXCARGO Therapeutics Inc
US$ 3,391
(-74,29%)
17,22M
EVTVEnvirotech Vehicles Inc
US$ 0,38
(-43,03%)
3,23M
IRWDIronwood Pharmaceuticals Inc
US$ 2,2791
(-38,73%)
7,29M
ZKINZK International Group Co Ltd
US$ 0,3011
(-37,98%)
2,13M
NVDANVIDIA Corporation
US$ 119,605
(-3,31%)
222,95M
CLEUChina Liberal Education Holdings Ltd
US$ 0,2077
(-97,32%)
192,79M
MGOLMGO Global Inc
US$ 0,1243
(22,22%)
146,46M
AMODAlpha Modus Holdings Inc
US$ 3,661
(137,73%)
115,23M
SPGCSacks Parente Golf Inc
US$ 0,876
(48,47%)
108,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
LIPO
Lipella Pharmaceuticals
BIT
UC7A8B
Unicredit Bank
DOWI
DWCFRN
DJ US Furnishings Total ...
LSE
BM88
Bpe Fin.0nts28
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces